Last Updated: May 10, 2026

Details for New Drug Application (NDA): 207923

✉ Email this page to a colleague

« Back to Dashboard

NDA 207923 describes SEEBRI NEOHALER, which is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. Additional details are available on the SEEBRI NEOHALER profile page.

The generic ingredient in SEEBRI NEOHALER is glycopyrrolate. There are seventeen drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

Summary for 207923

Tradename:	SEEBRI NEOHALER
Applicant:	Novartis
Ingredient:	glycopyrrolate
Patents:	2

Medical Subject Heading (MeSH) Categories for 207923

Adjuvants, Anesthesia
Muscarinic Antagonists

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	POWDER;INHALATION			Strength	15.6MCG/INH
Approval Date:	Oct 29, 2015	TE:		RLD:	Yes
Patent:	8,182,838	Patent Expiration:	Oct 20, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	8,479,730	Patent Expiration:	Oct 11, 2028	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 207923

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	8,048,451	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	6,582,678	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	6,521,260	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	8,580,306	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	9,931,304	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	9,962,338	⤷ Start Trial
Novartis	SEEBRI NEOHALER	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015	8,029,768	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.